Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyloidosis | 2 | 2024 | 66 | 1.710 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2024 | 126 | 1.610 |
Why?
|
| Skin Neoplasms | 10 | 2022 | 800 | 0.930 |
Why?
|
| Kidney Neoplasms | 8 | 2011 | 424 | 0.790 |
Why?
|
| Lymphoma | 1 | 2024 | 318 | 0.720 |
Why?
|
| Carcinoma, Renal Cell | 6 | 2010 | 235 | 0.700 |
Why?
|
| Skin | 2 | 2024 | 506 | 0.490 |
Why?
|
| Congo Red | 2 | 2024 | 7 | 0.460 |
Why?
|
| Kidney Diseases | 3 | 2009 | 479 | 0.440 |
Why?
|
| Amyloid | 2 | 2024 | 64 | 0.440 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2024 | 111 | 0.430 |
Why?
|
| Nephrectomy | 3 | 2009 | 172 | 0.380 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2011 | 69 | 0.350 |
Why?
|
| Acanthoma | 2 | 2022 | 5 | 0.350 |
Why?
|
| Adrenal Glands | 1 | 2008 | 47 | 0.310 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2008 | 65 | 0.300 |
Why?
|
| Kidney | 3 | 2010 | 1343 | 0.290 |
Why?
|
| Melanoma | 2 | 2012 | 834 | 0.290 |
Why?
|
| Pathology, Surgical | 2 | 2005 | 20 | 0.290 |
Why?
|
| Carcinoma | 2 | 2023 | 279 | 0.290 |
Why?
|
| Adenoma, Oxyphilic | 2 | 2008 | 9 | 0.280 |
Why?
|
| Kidney Diseases, Cystic | 2 | 2005 | 40 | 0.270 |
Why?
|
| PAX2 Transcription Factor | 3 | 2010 | 27 | 0.260 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 638 | 0.260 |
Why?
|
| Biopsy | 6 | 2024 | 1253 | 0.260 |
Why?
|
| Biomarkers, Tumor | 8 | 2023 | 1414 | 0.250 |
Why?
|
| Inclusion Bodies | 1 | 2005 | 45 | 0.240 |
Why?
|
| Mastocytosis, Cutaneous | 1 | 2024 | 4 | 0.240 |
Why?
|
| Plasma Cells | 1 | 2005 | 54 | 0.240 |
Why?
|
| Skin Diseases | 2 | 2022 | 121 | 0.230 |
Why?
|
| Mast Cells | 1 | 2024 | 75 | 0.230 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2023 | 8 | 0.220 |
Why?
|
| Mucins | 1 | 2024 | 74 | 0.220 |
Why?
|
| Diagnosis, Differential | 6 | 2017 | 1868 | 0.220 |
Why?
|
| Extremities | 1 | 2024 | 80 | 0.220 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2023 | 55 | 0.220 |
Why?
|
| Multiple Myeloma | 1 | 2005 | 171 | 0.210 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2022 | 38 | 0.210 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2022 | 33 | 0.210 |
Why?
|
| Keratosis, Actinic | 1 | 2022 | 12 | 0.210 |
Why?
|
| Drug Eruptions | 1 | 2021 | 33 | 0.190 |
Why?
|
| Adenine | 1 | 2021 | 99 | 0.190 |
Why?
|
| Humans | 37 | 2024 | 121793 | 0.190 |
Why?
|
| Aged | 12 | 2024 | 18732 | 0.180 |
Why?
|
| Referral and Consultation | 2 | 2005 | 524 | 0.180 |
Why?
|
| Piperidines | 1 | 2021 | 196 | 0.170 |
Why?
|
| Diagnostic Errors | 1 | 2003 | 319 | 0.170 |
Why?
|
| Insulin | 1 | 2024 | 1189 | 0.160 |
Why?
|
| Male | 22 | 2024 | 59243 | 0.150 |
Why?
|
| Carcinoid Tumor | 1 | 2017 | 21 | 0.140 |
Why?
|
| Parotid Neoplasms | 1 | 2016 | 14 | 0.140 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2016 | 20 | 0.140 |
Why?
|
| Middle Aged | 14 | 2024 | 25516 | 0.130 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 1582 | 0.130 |
Why?
|
| Thyroid Neoplasms | 2 | 2014 | 190 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 519 | 0.120 |
Why?
|
| Immunohistochemistry | 7 | 2014 | 1710 | 0.120 |
Why?
|
| Endoplasmic Reticulum | 3 | 2005 | 213 | 0.120 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2013 | 14 | 0.110 |
Why?
|
| Neck | 1 | 2014 | 134 | 0.110 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2013 | 20 | 0.110 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2013 | 23 | 0.110 |
Why?
|
| Hemangioma, Capillary | 1 | 2013 | 17 | 0.110 |
Why?
|
| Hemangiosarcoma | 1 | 2013 | 41 | 0.110 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2013 | 68 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 129 | 0.100 |
Why?
|
| Pathology | 1 | 2012 | 41 | 0.100 |
Why?
|
| Cadherins | 2 | 2010 | 164 | 0.100 |
Why?
|
| Granuloma, Pyogenic | 1 | 2012 | 5 | 0.100 |
Why?
|
| Vitiligo | 1 | 2012 | 6 | 0.100 |
Why?
|
| Photosensitivity Disorders | 1 | 2012 | 10 | 0.100 |
Why?
|
| Reminder Systems | 1 | 2012 | 60 | 0.100 |
Why?
|
| Sirolimus | 1 | 2013 | 220 | 0.100 |
Why?
|
| Melanoma, Amelanotic | 1 | 2011 | 2 | 0.100 |
Why?
|
| Nails | 1 | 2011 | 17 | 0.090 |
Why?
|
| Paired Box Transcription Factors | 1 | 2011 | 75 | 0.090 |
Why?
|
| Continuity of Patient Care | 1 | 2012 | 154 | 0.090 |
Why?
|
| Sarcoma, Kaposi | 1 | 2012 | 108 | 0.090 |
Why?
|
| Facial Dermatoses | 1 | 2009 | 8 | 0.090 |
Why?
|
| Retrospective Studies | 9 | 2024 | 15794 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 2 | 2009 | 866 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2010 | 207 | 0.080 |
Why?
|
| Granuloma | 1 | 2009 | 69 | 0.080 |
Why?
|
| Pheochromocytoma | 1 | 2008 | 33 | 0.080 |
Why?
|
| Adrenalectomy | 1 | 2008 | 35 | 0.080 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2012 | 645 | 0.080 |
Why?
|
| Ureteral Obstruction | 1 | 2009 | 107 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2010 | 391 | 0.070 |
Why?
|
| Frozen Sections | 2 | 2005 | 24 | 0.070 |
Why?
|
| Intraoperative Period | 2 | 2005 | 73 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1227 | 0.070 |
Why?
|
| Heart Transplantation | 1 | 2013 | 854 | 0.070 |
Why?
|
| Adult | 8 | 2024 | 28549 | 0.070 |
Why?
|
| Thapsigargin | 2 | 2003 | 23 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2012 | 690 | 0.060 |
Why?
|
| Urinary Bladder Diseases | 1 | 2005 | 35 | 0.060 |
Why?
|
| Neprilysin | 1 | 2005 | 19 | 0.060 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2005 | 24 | 0.060 |
Why?
|
| Hyalin | 1 | 2005 | 6 | 0.060 |
Why?
|
| Calcium Oxalate | 1 | 2005 | 24 | 0.060 |
Why?
|
| Caspases | 2 | 2003 | 160 | 0.060 |
Why?
|
| Microscopy, Electron | 2 | 2002 | 401 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 1206 | 0.060 |
Why?
|
| Neoplasm Proteins | 2 | 2013 | 669 | 0.060 |
Why?
|
| Tryptases | 1 | 2024 | 20 | 0.060 |
Why?
|
| Urticaria | 1 | 2024 | 18 | 0.060 |
Why?
|
| Dermatitis | 1 | 2024 | 25 | 0.060 |
Why?
|
| Gingiva | 1 | 2023 | 9 | 0.060 |
Why?
|
| Calcinosis | 1 | 2005 | 167 | 0.060 |
Why?
|
| Incidence | 1 | 2011 | 2962 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2023 | 55 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2005 | 315 | 0.050 |
Why?
|
| Rhabdomyoma | 1 | 2003 | 16 | 0.050 |
Why?
|
| Taurochenodeoxycholic Acid | 1 | 2002 | 4 | 0.050 |
Why?
|
| MART-1 Antigen | 1 | 2022 | 13 | 0.050 |
Why?
|
| SOXE Transcription Factors | 1 | 2022 | 15 | 0.050 |
Why?
|
| Cholagogues and Choleretics | 1 | 2002 | 25 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 1881 | 0.050 |
Why?
|
| Melanocytes | 1 | 2022 | 47 | 0.050 |
Why?
|
| Female | 9 | 2024 | 64573 | 0.050 |
Why?
|
| Scalp | 1 | 2022 | 56 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2023 | 396 | 0.050 |
Why?
|
| Mouth Neoplasms | 1 | 2003 | 78 | 0.050 |
Why?
|
| Cytoplasmic Structures | 1 | 2002 | 2 | 0.050 |
Why?
|
| Microvilli | 1 | 2002 | 73 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 653 | 0.050 |
Why?
|
| Streptococcus | 1 | 2001 | 61 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2023 | 194 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 759 | 0.050 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2003 | 242 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2023 | 352 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2013 | 4518 | 0.050 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 184 | 0.040 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 137 | 0.040 |
Why?
|
| HIV Infections | 1 | 2012 | 1842 | 0.040 |
Why?
|
| Neutrophils | 1 | 2001 | 371 | 0.040 |
Why?
|
| United States | 2 | 2012 | 10413 | 0.040 |
Why?
|
| Apoptosis | 2 | 2003 | 1791 | 0.040 |
Why?
|
| Streptococcal Infections | 1 | 2001 | 244 | 0.040 |
Why?
|
| Adolescent | 3 | 2024 | 18773 | 0.040 |
Why?
|
| Biopsy, Needle | 2 | 2012 | 232 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2012 | 6275 | 0.040 |
Why?
|
| Cheek | 1 | 2017 | 23 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2013 | 1073 | 0.040 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 1280 | 0.030 |
Why?
|
| Child | 3 | 2024 | 23789 | 0.030 |
Why?
|
| Neoplasms | 1 | 2011 | 2697 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 356 | 0.030 |
Why?
|
| Keratin-7 | 1 | 2014 | 7 | 0.030 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2014 | 14 | 0.030 |
Why?
|
| Thyroidectomy | 1 | 2014 | 100 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 76 | 0.030 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2013 | 5 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2013 | 28 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2013 | 144 | 0.030 |
Why?
|
| Caspase 12 | 2 | 2003 | 4 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2013 | 163 | 0.030 |
Why?
|
| Pneumonectomy | 1 | 2013 | 129 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2013 | 207 | 0.030 |
Why?
|
| Herpesvirus 8, Human | 1 | 2012 | 45 | 0.020 |
Why?
|
| Pruritus | 1 | 2012 | 41 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 697 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 283 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 2003 | 620 | 0.020 |
Why?
|
| PAX8 Transcription Factor | 1 | 2011 | 14 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 428 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 602 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 8676 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 879 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 232 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 860 | 0.020 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2011 | 87 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2012 | 399 | 0.020 |
Why?
|
| Adenoma | 1 | 2011 | 134 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 1976 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2003 | 13661 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 3297 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 3132 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 268 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2014 | 2580 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2005 | 381 | 0.010 |
Why?
|
| Time Factors | 1 | 2014 | 6168 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 2009 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 997 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 4953 | 0.010 |
Why?
|
| Genes, bcl-2 | 1 | 2003 | 11 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2003 | 53 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2003 | 44 | 0.010 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2003 | 37 | 0.010 |
Why?
|
| Lymphangioma | 1 | 2003 | 21 | 0.010 |
Why?
|
| Calpain | 1 | 2003 | 41 | 0.010 |
Why?
|
| Caspase 7 | 1 | 2002 | 6 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2003 | 55 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2002 | 130 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 173 | 0.010 |
Why?
|
| Sunlight | 1 | 2002 | 22 | 0.010 |
Why?
|
| Forearm | 1 | 2002 | 44 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2001 | 61 | 0.010 |
Why?
|
| Hemangioma | 1 | 2003 | 97 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2001 | 170 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2002 | 257 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2003 | 265 | 0.010 |
Why?
|
| Abscess | 1 | 2001 | 138 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 580 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 2792 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2002 | 383 | 0.010 |
Why?
|
| Infant | 1 | 2013 | 12177 | 0.010 |
Why?
|
| Mitochondria | 1 | 2002 | 679 | 0.010 |
Why?
|
| Calcium | 1 | 2002 | 1096 | 0.010 |
Why?
|
| Cell Line | 1 | 2002 | 2787 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2005 | 2031 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 17624 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2011 | 12003 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2003 | 959 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2003 | 1380 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 33870 | 0.010 |
Why?
|